Apricus Biosciences Inc. (NASDAQ:APRI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ®. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California. “

Apricus Biosciences (NASDAQ:APRI) traded up 0.308% during midday trading on Tuesday, hitting $0.326. 260,607 shares of the stock traded hands. The company’s 50-day moving average is $0.35 and its 200-day moving average is $0.40. Apricus Biosciences has a one year low of $0.28 and a one year high of $1.55. The company’s market cap is $21.63 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/apricus-biosciences-inc-apri-upgraded-to-hold-at-zacks-investment-research.html

Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. During the same quarter last year, the business posted ($0.10) earnings per share. Equities research analysts expect that Apricus Biosciences will post ($0.17) EPS for the current fiscal year.

An institutional investor recently raised its position in Apricus Biosciences stock. Healthcare Value Capital LLC increased its stake in Apricus Biosciences Inc. (NASDAQ:APRI) by 83.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 440,000 shares of the company’s stock after buying an additional 200,000 shares during the period. Apricus Biosciences makes up 0.4% of Healthcare Value Capital LLC’s investment portfolio, making the stock its 20th largest position. Healthcare Value Capital LLC owned 0.71% of Apricus Biosciences worth $256,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 23.83% of the company’s stock.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

5 Day Chart for NASDAQ:APRI

Get a free copy of the Zacks research report on Apricus Biosciences (APRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apricus Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.